<unk>  (IPST) is the formation of a new, increasing, or reappearing occlusive or non-occlusive thrombus of grade ≤2   that occurs before the completion of the percutaneous coronary intervention (PCI) procedure, and is specifically located within the recently deployed<unk>  or immediately adjacent to it. It is considered a rare subset of<unk>  thrombotic events (IPTE).  Although it rarely happens, it has been strongly associated with unfavorable periprocedural outcomes. It is defined as an angiographically confirmed intraluminal filling defect within the<unk>  that results in occlusive or non-occlusive thrombolysis in myocardial infarction (TIMI) grade-0 or 1 anterograde flow, secondary to the development of new or increasing thrombus within or adjacent to a recently implanted<unk> , occurring during the index procedure or before the percutaneous coronary intervention (PCI) is completed. It is also present when the baseline level of thrombus was decreasing or has resolved after balloon angioplasty or thrombus aspiration, but increased again any time after<unk>  implantation, including<unk>  postdilatation. In the large-scale CHAMPION PHOENIX trial, IPST was a relatively infrequent event, occurring in <1% of patients undergoing PCI, but was strongly associated with subsequent ischemic events, including out-of-laboratory ST, MI, and death. The reduction in IPST with cangrelor in CHAMPION PHOENIX contributed to this agent's effectiveness in reducing the rates of ARC-defined<unk><unk>  and MI. These data provide strong evidence for a significant association between IPST and adverse short-term clinical outcomes after PCI and support the inclusion of IPST as an important endpoint in future pharmacological and device trials.
Intraprocedural stent thrombosis
Abrupt closure during coronary intervention
Coronary artery ulceration
Coronary artery thrombus
Intraprocedural thrombotic events
Clopidogrel resistance
Coronary air embolism
No-reflow phenomenon